Navigation Links
Study Hints That Statins Might Fight Breast Cancer

By Denise Mann
HealthDay Reporter

THURSDAY, Jan. 19 (HealthDay News) -- Amid hints that statins -- cholesterol-lowering drugs -- might also play a role in preventing or treating certain types of cancer, new research sheds some light on how these drugs may help stop breast cancer in its tracks among certain women.

The p53 tumor suppressor gene stops the uncontrolled growth of cancer cells, but some women with breast cancer have mutant forms of this gene. In the new study, when the mutant p53 cells were treated in the laboratory with statins, the cells stopped their erratic growth, and even died in some cases.

It seems that the mutated p53 genes may activate the same pathway that the statins inhibit -- the mevalonate pathway, the study suggests. The mevalonate pathway is important in the body's production of cholesterol.

In the study, the effects of the statin drugs were erased when the mevalonate pathway was reactivated, supporting the potential mechanism. The new research is published in the Jan. 20 issue of the journal Cell.

Study author Dr. Carol Prives, chair of the department of biological sciences at Columbia University in New York City, is cautious in her enthusiasm about the results and their implications.

"The study is adding the possibility that there may be classes of breast cancer patients who will respond better to statins than others," she said, but noted that this research is far away from the bedside.

"By understanding better what sort of cells would respond to statins, one might have a better idea of whether or not to consider using them," she added. "The next step could be a trial of statins in women with breast cancer who have a mutated copy of the p53 gene."

Commenting on the study, cancer expert Marc Symons said, "This paper unravels a mechanism whereby p53, a frequently mutated cancer gene, promotes the aberrant behavior of cancer cells."

The mutated protein stimulates the mevalonate pathway, explained Symons, an investigator at the Center for Oncology and Cell Biology at the Feinstein Institute for Medical Research in Manhasset, N.Y.

"Statins, drugs that are widely used to lower cholesterol levels, block a key step in the mevalonate pathway," Symons said. "The new results may well give new momentum to the use of statins as anti-cancer agents."

Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, is also intrigued by the potential of the new findings.

"This paper addresses a possible new target for therapeutic agents based on a well-known tumor suppressor gene that is common in many cancers," Bernik said. "Identifying novel pathways that lead to tumor formation is the first step to developing new drugs that can specifically target some of the complex mechanisms that contribute to the development of cancer," she pointed out.

"This work and other projects like this raise the hope that we will one day be able to cure cancers on a molecular level," Bernik said.

More information

Learn more about how breast cancer is treated at the U.S. National Cancer Institute.

SOURCES: Carol Prives, Ph.D., DaCosta Professor of Biology and chair, department of biological sciences at Columbia University, New York City; Marc Symons, Ph.D., investigator, Center for Oncology and Cell Biology, Feinstein Institute of Medical Research, Manhasset, N.Y.; Stephanie Bernik, M.D., chief, surgical oncology, Lenox Hill Hospital, New York City; Jan. 20, 2012, Cell

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. VCU study suggests antimicrobial scrubs may reduce bacteria
2. Narrowed Artery Condition Often Goes Undiagnosed: Study
3. Some Women Can Go Longer Between Bone Checks: Study
4. Study reveals mechanism of lung-cancer drug resistance
5. Study finds potential key to immune suppression in cancer
6. The Pill Can Help Ease Period Pain, Study Finds
7. University of Maryland study: Headphone-distracted pedestrians face death, serious injury
8. Study reveals origins of esophageal cancer
9. Researchers study how chemicals in drugs and around us impact stem cells
10. UH Case Medical Center publishes study on novel treatment for skin lymphoma
11. Retention study identifies key factors affecting 3 generations of nurses
Post Your Comments:
Related Image:
Study Hints That Statins Might Fight Breast Cancer
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... Finnleo, ... through Christmas Eve on several models of traditional and far-infrared saunas. , ... Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at ... hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety ... fuller hair, without the need for surgery, prescription pills, or topical foams. , ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, ... Two Organizations, One Beat ” campaign. The partnership between the two groups began in ... in MAP International’s cause. , MAP International was founded in 1954 and is an ...
(Date:11/25/2015)... ... 2015 , ... Dental professionals who would like to become more proficient on ... Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on ... co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to ...
(Date:11/25/2015)... IL (PRWEB) , ... November 25, 2015 , ... The ... announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto and Alex ... Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... TEL AVIV, Israel , November 25, 2015 /PRNewswire/ ... firms (the "New Investors"), pursuant to which BioLight and ... in BioLight,s IOPtima Ltd. subsidiary ("IOPtima") via a private ... global commercialization of its innovative IOPtimate™ system used in ... a regulatory approval pathway process for the IOPtimate™ system ...
Breaking Medicine Technology: